Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rifampicin + isoniazid + pyrazinamide + ethambutol
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug is a fixed-dose combination of four first-line antituberculosis agents—rifampicin (also known as rifampin), isoniazid, pyrazinamide, and ethambutol. It is used primarily for the intensive phase of tuberculosis (TB) treatment in adults and children. Each component has a distinct mechanism of action against *Mycobacterium tuberculosis*: - **Rifampicin** inhibits DNA-dependent RNA polymerase in mycobacterial cells. - **Isoniazid** inhibits synthesis of mycolic acids essential for the bacterial cell wall. - **Pyrazinamide** disrupts membrane transport and energy production in mycobacteria. - **Ethambutol** inhibits arabinosyl transferase involved in cell wall biosynthesis. The combination aims to prevent resistance development by attacking TB bacteria through multiple mechanisms. It is taken orally and included on the World Health Organization's List of Essential Medicines[1][2][4][5][6].
- Brand names
- VoractivRimstarForecoxAkt 4Akt4Akt-4Akurit 4Akurit4Akurit-4MycuritR-Cinex EZTrac 4Trac4Trac-4AKT-FDMonto 4Monto4Monto-4Scc 4 LWScc4 LWScc-4 LWVicox EZ
- Other names
- ethambutol/isoniazid/pyrazinamide/rifampicin
02
Targets
embB (Arabinosyltransferase EmbB)FabI (Enoyl-acyl carrier protein reductase FabI)rpoB (DNA-directed RNA polymerase subunit beta)
Beyond the preview
Go deeper on rifampicin + isoniazid + pyrazinamide + ethambutol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rifampicin + isoniazid + pyrazinamide + ethambutol.